secwatch.observer — SEC 8-K summary
======================================

Issuer:     GRI Bio, Inc. (GRI)
CIK:        0001824293
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0001824293-22-000079
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vallon Pharma Q3 net loss $1.0M; cash $5.2M; strategic review ongoing
---------------------------------------------------------------------

- Net loss of $1.0M for Q3 2022; R&D expenses reversed to $(18,000) vs $0.2M in Q3 2021.
- G&A expenses $1.4M, up from $1.0M, driven by $0.6M in strategic evaluation costs.
- Cash, cash equivalents and marketable securities of $5.2M as of Sept 30, 2022.
- Strategic alternatives review with Ladenburg Thalmann remains ongoing; no transaction guaranteed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1824293/000182429322000079/0001824293-22-000079-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1824293/000182429322000079/ck00018242493-20221103.htm
  HTML page:      https://secwatch.observer/filing/0001824293-22-000079

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer